03:00 EST 20th January 2019 | BioPortfolio

Polysialylated DNase

PulmoXenTM is an improved form of DNase I, a recombinant human enzyme which is a genetically engineered version of a naturally occurring human enzyme. It is known to cleave extracellular DNA and hence reduce the viscosity of purulent and infected lung secretions (e.g., sputum of cystic fibrosis patients).  PulmoXen® is a performance-enhanced polysialylated form of DNase that is being developed to reduce the required frequency of dosage. The marketed form of DNase from Roche generated US$ 0.6 billion in sales. The compound is under pre-clinical studies.

PulmoXen is a polysialylated formulation of recombinant human DNase I, an enzyme which cleaves extracellular DNA thereby reducing the viscosity of purulent and infected lung secretions such as the sputum of cystic fibrosis patients. The agent is delivered using Xenetic’s PolyXen delivery technology which incorporates bacterial polysialic acid to increase the active life and improve pharmacokinetics and pharmacodynamics of peptides, proteins and small molecule drugs.

In preclinical studies, the technology has been shown to preserve drug functionality when conjugated, improve in vivo stability, prolong
pharmacological action and active life of drug in blood, reduce frequency and volume of dosage, and reduce immunogenicity and antigenicity.

Adapted from - Thomson Reuters Cortellis Competitive Intelligence

See also -

Quick Search


review and buy PulmoXen market research data and corporate reports here